Lynn Abel
Impact in
- Infectious Diseases top 2%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
-
- Intensive Care Unit Cognitive Disorders
Papers in
-
- COVID-19 Clinical Research Studies 6
- SARS-CoV-2 and COVID-19 Research 3
-
- interferon and immune responses 3
- Co-authors
- Clarence Henry Braddock (1 shared paper)Tina Hernandez‐Boussard (1 shared paper)Nancy L. Szaflarski (1 shared paper)John Magaña Morton (1 shared paper)
- Journals
- JAMA (7 papers)Nature (4 papers)The Lancet (2 papers)JAMA Network Open (1 paper)BMC Cardiovascular Disorders (1 paper)
- Partner nations
- United KingdomUnited States
In The Last Decade
Lynn Abel
18 papers receiving 1.9k citations
Lynn Abel's Hit Papers
Peers
Comparison fields: 5 of 112
- Infectious Diseases 863
- Critical Care and Intensive Care Medicine 94
- Neurology 287
- Immunology 291
- Internal Medicine 30
Countries citing papers authored by Lynn Abel
This map shows the geographic impact of Lynn Abel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lynn Abel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lynn Abel more than expected).
Fields of papers citing papers by Lynn Abel
This network shows the impact of papers produced by Lynn Abel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lynn Abel. The network helps show where Lynn Abel may publish in the future.
Co-authors
The 4 scholars most cited alongside Lynn Abel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Mapping the human genetic architecture of COVID-19 Hit paper breakdown → | 2021 | 641 |
| 2 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 230 |
| 3 | Whole-genome sequencing reveals host factors underlying critical COVID-19 Hit paper breakdown → | 2022 | 228 |
| 4 | 2021 | 163 | |
| 5 | GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19 Hit paper breakdown → | 2023 | 121 |
| 6 | 2022 | 104 | |
| 7 | 2022 | 99 | |
| 8 | 2023 | 83 | |
| 9 | 2023 | 62 | |
| 10 | 2023 | 56 | |
| 11 | 2023 | 45 | |
| 12 | 2023 | 34 | |
| 13 | 2014 | 24 | |
| 14 | 2025 | 16 | |
| 15 | 2023 | 9 | |
| 16 | 2024 | 8 | |
| 17 | 2025 | 1 | |
| 18 | 2025 | 1 |
About Lynn Abel
Lynn Abel is a scholar working on Infectious Diseases, Immunology, Epidemiology, Critical Care and Intensive Care Medicine and Genetics, having authored 18 papers that have together received 1.9k indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (6 papers), interferon and immune responses (3 papers), SARS-CoV-2 and COVID-19 Research (3 papers), Sepsis Diagnosis and Treatment (2 papers), Pneumonia and Respiratory Infections (1 paper), Liver Disease Diagnosis and Treatment (1 paper), Intensive Care Unit Cognitive Disorders (1 paper) and Respiratory viral infections research (1 paper). The work is most often cited by research in Infectious Diseases (863 citations), Critical Care and Intensive Care Medicine (94 citations), Neurology (287 citations), Immunology (291 citations) and Internal Medicine (30 citations). Lynn Abel has collaborated with scholars based in United Kingdom and United States. Frequent co-authors include Clarence Henry Braddock, Tina Hernandez‐Boussard, Nancy L. Szaflarski and John Magaña Morton. Their work appears in journals such as JAMA, Nature, The Lancet, JAMA Network Open and BMC Cardiovascular Disorders.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.